Scholar Rock Holding (SRRK) Free Cash Flow (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Free Cash Flow of -$82.1 million for Q1 2026, down 4.04% year-over-year from -$85.6 million in Q1 2025, and down 8.75% quarter-over-quarter from -$75.5 million in Q4 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Free Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Free Cash Flow history runs 10 years deep, the most recent figure standing at -$82.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 4.04% year-over-year to -$82.1 million; the TTM figure through Mar 2026 stood at -$303.8 million (down 31.8% YoY), while the FY2025 annual figure was -$300.6 million, down 49.54% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$82.1 million, down from -$75.5 million in the prior quarter.
- The five-year high for Free Cash Flow was -$26.5 million in Q3 2022, with the low at -$82.1 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$49.5 million (2024), against an average of -$50.9 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow climbed 29.03% in 2022, then sank 61.87% in 2024.
- Scholar Rock Holding's Free Cash Flow stood at -$29.9 million in 2022, then tumbled by 35.42% to -$40.4 million in 2023, then fell by 24.2% to -$50.2 million in 2024, then slumped by 50.4% to -$75.5 million in 2025, then retreated by 8.75% to -$82.1 million in 2026.
- Business Quant data shows SRRK's Free Cash Flow at -$82.1 million in Q1 2026, -$75.5 million in Q4 2025, and -$69.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Scholar Rock Holding | 7.25 Bn | 7.25 Bn | - | -68.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -68.45 Mn |
| Mar 31, 2026 | -82.17 Mn |
| Dec 31, 2025 | -75.53 Mn |
| Sep 30, 2025 | -69.01 Mn |
| Jun 30, 2025 | -77.16 Mn |
| Mar 31, 2025 | -78.95 Mn |
| Dec 31, 2024 | -48.65 Mn |
| Sep 30, 2024 | -52.47 Mn |
| Jun 30, 2024 | -48.89 Mn |
| Mar 31, 2024 | -49.47 Mn |
| Dec 31, 2023 | -40.43 Mn |
| Sep 30, 2023 | -32.00 Mn |
| Jun 30, 2023 | -32.50 Mn |
| Mar 31, 2023 | -42.99 Mn |
| Dec 31, 2022 | -29.02 Mn |
| Sep 30, 2022 | -26.51 Mn |
| Jun 30, 2022 | -35.22 Mn |
| Mar 31, 2022 | -43.01 Mn |
| Dec 31, 2021 | -33.00 Mn |
| Sep 30, 2021 | -37.39 Mn |